5 Key Takeaways

• 1

  Uveitic macular edema is a leading cause of vision loss in uveitis patients, with nearly 50% experiencing persistent edema despite treatment.

• 2

  Vamikibart, an IL-6 targeting molecule, showed promising results in phase 3 trials, improving visual acuity by about 10 letters compared to sham.

• 3

  Both doses of vamikibart demonstrated safety with low rates of intraocular inflammation, cataract, and intraocular pressure complications.

• 4

  The pharmacokinetic data indicated that IL-6 suppression with vamikibart lasts up to 6 months, suggesting potential durability in treatment.

• 5

  The ongoing analysis of full-year data will help determine the injection frequency needed for effective management of uveitic macular edema.